Bank of Nova Scotia’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.47M | Sell |
60,417
-20,437
| -25% | -$1.71M | 0.01% | 605 |
|
|
2026
Q1 | $6.47M | Sell |
80,854
-12,818
| -14% | -$1.06M | 0.01% | 527 |
|
|
2025
Q4 | $7.99M | Sell |
93,672
-59,396
| -39% | -$4.87M | 0.01% | 534 |
|
|
2025
Q3 | $11.9M | Buy |
153,068
+50,264
| +49% | +$3.93M | 0.02% | 389 |
|
|
2025
Q2 | $8.04M | Buy |
102,804
+13,132
| +15% | +$979K | 0.02% | 427 |
|
|
2025
Q1 | $6.5M | Sell |
89,672
-126,932
| -59% | -$9.09M | 0.01% | 422 |
|
|
2024
Q4 | $16M | Buy |
216,604
+36,345
| +20% | +$2.54M | 0.03% | 328 |
|
|
2024
Q3 | $11.9M | Buy |
180,259
+3,411
| +2% | +$248K | 0.02% | 322 |
|
|
2024
Q2 | $16.3M | Sell |
176,848
-755,915
| -81% | -$66.9M | 0.03% | 288 |
|
|
2024
Q1 | $89.1M | Buy |
932,763
+569,144
| +157% | +$47.8M | 0.18% | 101 |
|
|
2023
Q4 | $27.7M | Sell |
363,619
-348,691
| -49% | -$24.3M | 0.05% | 248 |
|
|
2023
Q3 | $49.3M | Buy |
712,310
+364,563
| +105% | +$29.3M | 0.13% | 132 |
|
|
2023
Q2 | $32.8M | Sell |
347,747
-58,003
| -14% | -$5.04M | 0.09% | 162 |
|
|
2023
Q1 | $33.6M | Sell |
405,750
-496,242
| -55% | -$39M | 0.1% | 153 |
|
|
2022
Q4 | $67.3M | Buy |
901,992
+492,193
| +120% | +$37.9M | 0.17% | 109 |
|
|
2022
Q3 | $33.8M | Buy |
409,799
+5,098
| +1% | +$491K | 0.11% | 157 |
|
|
2022
Q2 | $38.5M | Sell |
404,701
-13,489
| -3% | -$1.4M | 0.09% | 189 |
|
|
2022
Q1 | $49.2M | Sell |
418,190
-631,991
| -60% | -$70.9M | 0.08% | 193 |
|
|
2021
Q4 | $136M | Buy |
1,050,181
+418,306
| +66% | +$48.8M | 0.19% | 120 |
|
|
2021
Q3 | $71.5M | Sell |
631,875
-57,892
| -8% | -$6.61M | 0.13% | 159 |
|
|
2021
Q2 | $71.4M | Buy |
689,767
+389,690
| +130% | +$36.7M | 0.13% | 145 |
|
|
2021
Q1 | $25.1M | Sell |
300,077
-83,193
| -22% | -$7.03M | 0.05% | 271 |
|
|
2020
Q4 | $35M | Buy |
383,270
+31,511
| +9% | +$2.61M | 0.07% | 217 |
|
|
2020
Q3 | $28.1M | Buy |
351,759
+249,869
| +245% | +$19.5M | 0.08% | 215 |
|
|
2020
Q2 | $7.04M | Sell |
101,890
-721,157
| -88% | -$51.3M | 0.02% | 364 |
|
|
2020
Q1 | $51.6M | Buy |
823,047
+263,283
| +47% | +$19M | 0.18% | 116 |
|
|
2019
Q4 | $43.5M | Buy |
559,764
+326,742
| +140% | +$25.5M | 0.11% | 178 |
|
|
2019
Q3 | $17.1M | Buy |
233,022
+112,407
| +93% | +$7.9M | 0.05% | 289 |
|
|
2019
Q2 | $7.43M | Buy |
120,615
+3,555
| +3% | +$215K | 0.03% | 342 |
|
|
2019
Q1 | $7.47M | Sell |
117,060
-16,986
| -13% | -$969K | 0.03% | 357 |
|
|
2018
Q4 | $6.84M | Sell |
134,046
-116,361
| -46% | -$5.89M | 0.03% | 338 |
|
|
2018
Q3 | $14.5M | Buy |
250,407
+173,364
| +225% | +$8.48M | 0.06% | 247 |
|
|
2018
Q2 | $3.74M | Sell |
77,043
-3,156
| -4% | -$147K | 0.02% | 391 |
|
|
2018
Q1 | $3.73M | Sell |
80,199
-18,993
| -19% | -$825K | 0.02% | 437 |
|
|
2017
Q4 | $3.73M | Sell |
99,192
-10,635
| -10% | -$390K | 0.02% | 461 |
|
|
2017
Q3 | $4M | Sell |
109,827
-32,358
| -23% | -$1.23M | 0.02% | 419 |
|
|
2017
Q2 | $5.6M | Buy |
+142,185
| New | +$5.19M | 0.03% | 411 |
|
|
2017
Q1 | – | Sell |
-14,130
| Closed | -$441K | – | 897 |
|
|
2016
Q4 | $441K | Buy |
14,130
+1,230
| +10% | +$39.9K | ﹤0.01% | 625 |
|
|
2016
Q3 | $518K | Buy |
12,900
+30
| +0.2% | +$1.13K | ﹤0.01% | 517 |
|
|
2016
Q2 | $428K | Sell |
12,870
-122,850
| -91% | -$4.2M | ﹤0.01% | 525 |
|
|
2016
Q1 | $3.99M | Buy |
135,720
+123,750
| +1,034% | +$3.41M | 0.02% | 242 |
|
|
2015
Q4 | $315K | Sell |
11,970
-75,660
| -86% | -$1.96M | ﹤0.01% | 598 |
|
|
2015
Q3 | $2.08M | Buy |
87,630
+75,900
| +647% | +$1.83M | 0.01% | 261 |
|
|
2015
Q2 | $278K | Buy |
11,730
+276
| +2% | +$6.23K | ﹤0.01% | 499 |
|
|
2015
Q1 | $272K | Sell |
11,454
-726
| -6% | -$16.3K | ﹤0.01% | 502 |
|
|
2014
Q4 | $259K | Buy |
+12,180
| New | +$245K | ﹤0.01% | 487 |
|
Other funds holding EW
Bank of Nova Scotia's EW Position: Q2 2026 in Review
Bank of Nova Scotia reduced its Edwards Lifesciences (EW) stake by 25% in Q2 2026, selling an estimated $1.71M and leaving 60,417 shares worth $5.47M. The position accounts for 0.01% of the portfolio, ranked #605.
Bank of Nova Scotia first reported a position in EW in Q4 2014 and has held it in 46 quarters since. The position peaked at $136M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Bank of Nova Scotia held 60,417 shares of Edwards Lifesciences worth $5.47M as of Q2 2026.
- Bank of Nova Scotia sold 20,437 Edwards Lifesciences shares in Q2 2026, an estimated $1.71M.
- Edwards Lifesciences made up 0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #605 holding.
- Bank of Nova Scotia first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 46 quarters since.
- Bank of Nova Scotia's Edwards Lifesciences position peaked at $136M in Q4 2021.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.